Compare Amphastar Pharmaceuticals Inc (AMPH) vs Johnson Controls International PLC (JCI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Johnson Controls International PLC — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Johnson Controls International PLC trades at $142.77 (market cap $87.13B). The key difference: Johnson Controls International PLC is far larger — about 105.5× Amphastar Pharmaceuticals Inc's market cap, and Johnson Controls International PLC pays a 1.12% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | JCI | |
|---|---|---|
Market Cap | $826.08M | $87.13B |
Sector | Health | Industrials |
52-Week High | $30.81 | $148.21 |
52-Week Low | $16.87 | $103.24 |
Enterprise Value | $1.22B | $95.96B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Johnson Controls International (JCI) trades at $142.81, up 1.62% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with a net income margin of 14.45% and a consensus analyst price target of $153.67. Recent news highlights expansion in data center cooling and smart home markets, supported by a dividend of $0.40 per share payable in July 2026.
JCI's outlook is supported by earnings momentum and strategic acquisitions, but risks include high valuation multiples and bearish technical indicators. The stock offers potential upside to analyst targets, though investors should monitor debt levels and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →
